GRIMES & Co WEALTH MANAGEMENT LLC Grows Stock Position in Boston Scientific Corporation $BSX

GRIMES & Co WEALTH MANAGEMENT LLC increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 188.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,409 shares of the medical equipment provider’s stock after purchasing an additional 15,947 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Boston Scientific were worth $2,383,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Steph & Co. acquired a new stake in shares of Boston Scientific in the 3rd quarter worth $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific in the third quarter valued at about $25,000. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter valued at approximately $26,000. Sound Income Strategies LLC increased its position in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the period. Finally, Kilter Group LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 93,095 shares of company stock valued at $9,305,450 over the last quarter. Insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on BSX. UBS Group restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Wells Fargo & Company upped their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. BTIG Research reissued a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $125.21.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint PFA catheter expands BSX’s electrophysiology portfolio and supports procedure-driven recurring revenue; regulatory win should accelerate commercial roll‑out in atrial fibrillation ablation. Article Title
• Positive Sentiment: Agreement to acquire Valencia Technologies broadens BSX’s pelvic/uroLOGY offering for urinary incontinence and overactive bladder — gives exposure to a high-growth segment and supports the company’s stated pelvic-health strategy. (Official release) Article Title
• Positive Sentiment: J.P. Morgan coverage/notes highlight expectations for strong PFA performance in 2026 and beyond, reinforcing growth prospects for BSX’s higher‑margin electrophysiology portfolio. Article Title
• Positive Sentiment: Bank of America (analyst Travis Steed) reaffirmed a Buy rating and a $120 price target, citing strategic pelvic‑health expansion and the Valencia deal as upside drivers. Article Title
• Positive Sentiment: Sector write‑ups note BSX is benefiting from favorable product‑mix shifts toward higher‑margin devices, supporting margin expansion and durable revenue growth. Article Title
• Neutral Sentiment: Management’s JP Morgan conference presentation/transcript provides updated strategic context and reinforcement of guidance, useful for modeling but not a discrete catalyst by itself. Article Title
• Negative Sentiment: Short‑term sell pressure: some coverage noted the stock fell despite a strong market day and higher volume — suggesting profit‑taking, rotation away from richly valued medtech names (BSX’s trailing P/E is elevated) may be weighing on the share price. Article Title

Boston Scientific Trading Down 1.8%

Shares of BSX opened at $94.02 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The stock has a market cap of $139.37 billion, a price-to-earnings ratio of 50.28, a price-to-earnings-growth ratio of 1.69 and a beta of 0.67. The firm has a 50 day simple moving average of $97.43 and a 200-day simple moving average of $100.58.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s revenue was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.